Sumitomo Pharma America
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sumitomo Pharma America sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).
Sumitomo Pharma America: 168 sponsored US clinical trials, 6 recruiting.
Sumitomo Pharma America sponsors 168 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 142 completed. 83 of these trials are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 4 trials.
Top-decile sponsor footprint
Sumitomo Pharma America ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
142 of 159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
168 total, page 1 of 4
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
NCT07444268
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
NCT06891885
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
NCT06753331
SMP-3124LP in Adults With Advanced Solid Tumors
NCT06526819
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
NCT04988555
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT04176198
A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)
NCT06517940
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
NCT05467176
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
NCT05023551
TP-3654 Food Effect Study
NCT07492355
A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.
NCT06037668
Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654
NCT06389955
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
NCT05605964
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
NCT05227209
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
NCT05169710
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
NCT04666129
A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS
NCT04623996
Phase 1 Study of Oral TP-1454
NCT04328740
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
NCT04299880
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
NCT03969420
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
NCT03572634
Study of TP-3654 in Patients With Advanced Solid Tumors
NCT03715504
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
NCT03604783
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
NCT03593915
First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors
NCT03429218
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
NCT03543410
A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
NCT03627195
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
NCT03416335
A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects
NCT03525405
A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
NCT03416816
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
NCT03311334
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
NCT03149003
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
NCT03298984
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
NCT03292016
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
NCT03187301
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
NCT03231800
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
NCT03116828
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers
NCT03411122
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
NCT03107026
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
NCT02729298
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
NCT02993731
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
NCT02826161
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
NCT02753127
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
NCT02795637
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
NCT02734693
Alvocidib Biomarker-driven Phase 2 AML Study
NCT02520011
Dasotraline Binge Eating Disorder Extension Study
NCT02684279
An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate
NCT02520557
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
NCT02498665
Dasotraline Binge Eating Disorder Study
NCT02564588
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 27 |
| Phase 3 | 75 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Sumitomo Pharma America pipeline
6 recruiting of 168 indexed (4% open); 142 completed (85%).
Phase mix: 83 late (III/IV) vs 80 early (I/II) (balanced across stages).
Top condition: Schizophrenia (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sumitomo Pharma America: open-pipeline peers nationwide
Peers matched on 168 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Sumitomo Pharma America sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 168 trials (± recruiting share)
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Bausch Health Americas · 168 trials · 4% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
- University of New Mexico · 168 trials · 1% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Bayer · 4% recruiting · 591 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
Related
What to do with this Sumitomo Pharma America page
168 registered trials is a research-attention snapshot, not an endorsement of Sumitomo Pharma America or any single study.
- 6 of Sumitomo Pharma America's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Sumitomo Pharma America studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sumitomo Pharma America pipeline card: 168 registered trials from official public datasets.Report a data error.